



CIN No. : L24239DL2004PLC125888

## AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

---

Ref: Akums/Exchange/2024-25/ 29

November 09, 2024

**To,  
The Listing Department  
National Stock Exchange of India Ltd  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051**

**To,  
The Listing Department  
BSE Limited  
Rotunda Building, Phiroze  
Jeejeebhoy Towers, Dalal Street,  
Fort, Mumbai – 400 001**

**Symbol: AKUMS**

**Scrip Code: 544222**

**Sub: Press Release**

Respected Sir/Madam,


Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of press release is enclosed herewith.

This is for your kind information and record.

Thanking You

**For Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik  
Company Secretary & Compliance Officer



ISO 9001 : 2015  
ISO 14001 : 2015  
ISO 17025 : 2005 (NABL)

WHO-GMP  
US : NSF  
H A C C P



Akums Q2 PAT up 16% from previous quarter

New Delhi, November 9, 2024: Akums Drugs and Pharmaceuticals Ltd. India's largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter ending September 30, 2024, marking 16% increase in profit after tax (PAT) on sequential quarter-on-quarter basis.

Key Highlights:

Quarter ended September 30, 2024	Half-year ended September 30, 2024
<ul style="list-style-type: none"> <li>Adjusted PAT of Rs 667 million   up 16.2% QoQ   up 8.9% YOY</li> <li>Adj EBITDA Margin at 12.9%; Adj PAT Margin at 6.4%</li> <li>Total Income at Rs 10,466 million   Growth of 2.0% QoQ   Reduction of 11.9% YoY</li> <li>Adjusted EBITDA of Rs 1,347 million   up 3.0% QoQ   down 28.0% YoY</li> </ul> <p>Segmental</p> <ul style="list-style-type: none"> <li>CDMO EBITDA of Rs 1,227 million   up 1.3% QoQ   down 34.8% YOY</li> <li>Branded and Generic EBITDA of Rs 180 million   up 5.2% QoQ   up 116% YOY</li> <li>API EBITDA at Rs -143 million</li> </ul>	<ul style="list-style-type: none"> <li>Adjusted PAT of Rs 1,240 million   up 25.4%</li> <li>Adj EBITDA Margin at 12.8%; Adj PAT Margin at 6.0%</li> <li>Total Income at Rs 20,722 million   Reduction of 4.3% YoY</li> <li>Adjusted EBITDA of Rs 2,654 million   down 10.1% YoY</li> <li>Cash surplus at Rs 3,406 million</li> </ul> <p>Segmental</p> <ul style="list-style-type: none"> <li>CDMO EBITDA of Rs 2,439 million   down 17.3% YOY</li> <li>Branded and Generic EBITDA of Rs 351 million   up 124% YOY</li> <li>API EBITDA at Rs -264 million</li> </ul>

For Q2, Akums reported a consolidated total income of ₹10,466 million, representing a sequential growth of 2%. Adjusted EBITDA was recorded at ₹1,347 million, a 3% rise over the previous quarter, while the adjusted PAT stood at ₹667 million, a 16% increase. The company's adjusted EBITDA margin of 12.9% and PAT margin of 6.4% reflect operational efficiency and a focus on profitable growth. However, the YoY comparison reflects the impact of lower API prices and fluctuating demand, which Akums remains optimistic will stabilize as it expands its footprint.

The company's cash surplus position remains robust at ₹3,406 million, which is instrumental in supporting further investment in R&D and expanding production and business capabilities.

Sanjeev Jain, Managing Director, also shared his views, stating, "Short term volatility apart, we continue to see strong secular demand for outsourced drug development and manufacturing. We will continue to invest in building world-class capabilities to help our clients launch new formulations and therapies, and drive their growth. The company is taking long term measures to further strengthen its leadership position in the CDMO space."

Sandeep Jain, Managing Director, stated, "Our focus continues to be on the development of innovative products and platforms, exploring more markets towards our larger objective of driving profitable growth. Q2 business performance reflects the muted volume demand and low API prices. We remain committed to our long term vision of being a global CDMO player".